OnCo
ideasIdea

Implant a tiny device that tests twenty drugs inside the patient's own tumour

A rice-grain-sized implant can release small doses of many different drugs into separate spots of a tumour, then be removed so doctors can see which one worked in that person.

Implantable microdevices developed at MIT and Brigham and Women's Hospital deliver microdoses of up to 20 agents into spatially separated tumour regions for 24-72 hours before retrieval and analysis, and first-in-human studies have been performed in breast, sarcoma and brain tumours. Applied to immune-modulating agents, the device measures local pharmacodynamics in the real human microenvironment, which no model reproduces.

Hypothesis
Microdevice-derived local response ranking predicts subsequent systemic response to the same agent, giving a functional assay for immunotherapy combinations that tissue genomics cannot provide.
Rationale
The core problem in combination immunotherapy is a combinatorial space far larger than trial capacity. In-patient microdosing tests many agents per patient rather than one, converting an intractable search into a measurable screen.
What would test it
Prospective study in patients scheduled for resection: implant, retrieve, profile, then follow subsequent systemic therapy outcomes to test the concordance between local ranking and clinical response.
Maturity
early clinical
Who has to act
engineering
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks

Connected

11top

Pages like this

not linked directly; found by shared links